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1. Introduction 
Hemopexin is the serum /.I-glycoprotein with a high 
affinity for heme [ 1 ] and its biological and physico- 
chemical properties have been reviewed by Muller- 
Eberhard and Liem [2]. The detailed characterization 
of the protein is hampered by the complexity and 
low yields of the isolation procedures, specially for 
human hemopexin [3-51. 
In an attempt to explain differences in purification 
procedures of human hemopexin, we present here 
experimental evidence for a change in its isoelectric 
point upon heme-binding. It provides information on 
the change in the conformation of hemopexin induced 
by its interaction with heme and thus may contribute 
for understanding the means by which hemopexin 
fulfills its physiological function in heme transport. 
2. Experimental 
2.1. Isolation of a crude hemopexin fraction 
The human serum fractionation technique by 
rivanol and ammonium sulfate was that of Hayem-Levy 
and Havez [3], with slight modifications. Ammonium 
sulfate concentrations were lower. Transferrin elimina- 
tion was checked by radial immuno-diffusion using 
partigen Behring. 
All operations were carried out at 4’C. The serum 
came from a pool saved after clinical analysis and was 
dialysed against NaCl 1.17%. One liter was diluted 
with one liter of 0.8% NaCl. Successive precipitates 
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obtained under the following conditions were dis- 
carded after 90 min centrifugation at 3000 X g: 
(i) One liter of 2.50% rivanol solution in 0.05 M, 
pH 8.0, phosphate buffer was added dropwise, under 
stirring, overnight. 
(ii) NaCl to a 5% final concentration, citric acid 
to adjust pH at 7.0 and ammonium sulfate, to a 0.96 
M final concentration, were added. 
(iii) Citric acid lowered pH to 3.8. 
(iv) Ammonium sulfate was added to 1.3 1 M final 
concentration. 
Finally a 2.91 M ammonium sulfate precipitate was 
dialysed against 10 mM Tris-HCl buffer, pH 7.0, in a 
Biorad ‘50’ bioflber beaker. Protein concentration 
was adjusted between 10 mg/ml and 20 mg/ml. The 
resulting fraction was named Fraction A. 
2.2. Displacement chromatography 
Tris-HCl buffer 10 mM, pH 7.0, was used for 
equilibration and for elution of the column 
(3.5 X 10 cm) of DEAE-Sephadex A-50 at 4°C. 
Experimental conditions are given in the legend to flg.1. 
Elution was followed by absorbance measurements at 
280 nm and 414 nm, by the rockett technique of 
Svendsen and Carsten [6] and by radial immuno- 
diffusion with partigen Behring for hemopexin. Immuno- 
electrophoresis was performed using whole human 
serum protein antiserum, specific anti-human hapto- 
globin antiserum and specific anti-human hemopexin 
antiserum (fig.2). Haptoglobin concentration was 
determined by the Hyland method used in clinical 
analysis. Crossed immunoelectrophoresis was then 
realised according to Laurel1 [7] . After analysis, hemo- 
pexin containing fractions of displacement chromato- 
graphy were pooled and named Fraction B. 
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A rabbit antiserum raised against this Fraction I3 
was prepared and used in Laurel1 technique with a 
fresh normal, non-hemolysed human serum as antigen. 
Absence of hemolysis was ascertained by potassium 
measurement with flame spectrophotometry. 
3. Results 
After precipitation steps, Fraction A consisted of 
10% hemopexin with a yield of 33%. 
Figure 1 shows the elution profile of displacement 
chromatography. Pooled fractions or Fraction B con- 
sisted of less retained proteins, whose interactions with 
the exchanger were weak. The exchanger was not over- 
saturated since the composition of the plateau was con- 
stant. As shown in fig.2 the only contaminant found 
was haptoglobin, its level was 5% of the whole proteins. 
The final recovery was 16% of serum hemopexin. Puri- 
fication was not carried out any further for haptoglobin 
elimination by a gel-filtration step as described by 
Hayem-Levy and Havez [3], but haptoglobin was kept 
as an internal marker for electrophoretic study. Its 
position in crossed immuno-electrophoresis was ascer- 
tained using specific antihaptoglobin antiserum as 
control for each of the following plates. It migrated in 
the medium of the plates, and could be distinguished 




Fig. 1. Displacement chromatography on DEAE-Sephadex 
A-50 of Fraction A. Buffer: Tris-HCl, 50 mM, pH 7.0. 
Fraction A obtained from 2 liters of serum at a protein con- 
centration of lo-20 mg/ml (i.e., about 300 ml) was deposed. 
Flow rate: 36 ml/h. Column: 3.5 X 10 cm. Fraction volume: 
7.5 ml. ( -) Optical density at 414 nm. (- - -=- -) 
Hemopexin determination by radial hnmunodiffusion. Pooled 
fractions were named Fraction B. 
Fig.2. Immunoelectrophoresis of Fraction B. (a) Anti-whole 
human serum protein antiserum. (b) Specific anti-human 
haptoglobin antiserum. (c) Specific anti-human hemopexin 
antiserum. 
Figure 3 shows Laurel1 plates of Fraction B as 
antigen against anti-whole human serum protein anti- 
serum (fig.3A). The major protein fraction split into 
two peaks, the one noted 1, faster, and the other one 
noted 2, slower than haptoglobin after the first dimen- 
sion electrophoresis. 
In order to study this splitting after electrophoretic 
migration, normal non-hemolysed human serum was 
used as antigen in the first dimension, with antiserum 
Fig.3A 
292 
Volume 78, number 2 FEBS LETTERS June 1977 
Fig.3B 
Fig.3C 
Fig.3. Laurell plates of Fraction B. (Hp) Haptoglobin. (Hpx) 
Hemopexin. (3A) Antigen: Fraction B. Antiserum: an&whole 
human serum protein. (3B) Antigen: Normal, fresh, non- 
hemolyzed human serum. Antiserum: Antiserum raised against 
fraction B. (3C) Antigen: Normal, fresh, non-hemolyzed 
human serum. Heme in equimolecular amount to Hpx was 
added in the well. Antiserum: Antiserum raised against 
Fraction B. 
raised against Fraction B in the second dimension. 
Figure 3B shows a major peak noted 2, slower than 
haptoglobin. Moreover, there is a less important bow 
still slower and noted 3 on fig.3B, this bow seems to 
enclose several precipitation lines, one of them is the 
same for both peak 2 and peak 1. It may be polymers 
whose high molecular weight hindered migration 
through gelose. 
6 Finally, in fig.3C, heme was dissolved in the electro- 
phoresis buffer and added in equimolecular amounts 
with hemopexin to the same serum in the well. It 
caused firstly, the apraisal of peak 1 of fig.3A, secondly, 
it abolished peak 3 of fig.3B. In order to keep heme- 
saturated and heme-depleted hemopexin in the same 
plate, optimal incubation was not achieved, the only 
equimolecular heme addition just before migration 
suffice to show the two forms together. 
Thus peak 1 seems to be heme-hemopexin, peak 2 
apo-hemopexin and peak 3 polymers. 
4. Discussion 
These results may provide a means for improving 
preparation procedure, moreover, they confirm 
available physico-chemical data. 
The isolation method reported by Hayem-Levy and 
Havez [3] involves the use of precipitation of human 
serum with rivanol and ammonium sulfate, followed by 
gel-filtration. Heme-hemopexin and apo-hemopexin 
are then isolated together. Heme is reported a poly- 
merising agent, and therefore may diminish hemopexin 
monomer recovery after the gel-filtration step. 
In the method of Aisen et al. [4], Cohn fraction 
IV-7 is submitted to ion-exchange chromatography and 
then to gel-filtration. These authors obtained mono- 
meric apo-hemopexin; heme-hemopexin was lost. 
Hrkal et al. [5] added heme in the course of the 
fractionation procedure, elution of ion-exchange 
chromatography was followed by A414 nm and 
provided heme-hemopexin and its aggregated form. 
Suttnar et al. [8] employed affinity chromato- 
graphy for human hemopexin, although hemopexin 
was eluted in three peaks no differences in the purity 
of the three fractions were found on acrylamide gel 
electrophoresis, and immunoelectrophoresis. 
In each procedure hitherto reported in literature 
either apo-hemopexin, heme-hemopexin or polymerised 
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hemopexin was lost and contribute to diminish yield. 
Data presented here furnish experimental evidence for 
preexisting of these three states of the molecule in 
native serum. 
Heme is known to facilitate hemopexin aggrega- 
tion [3]. The present experiments provide evidence 
that in the presence of a sufficient amount of heme, 
such aggregates will disappear, if hemopexin has kept 
its binding properties. 
The chief difficulty is to know what exact propor- 
tion of heme may be bound by hemopexin in serum 
after bleeding. Dissociation of the complex was never 
achieved in the literature. In Hrkal et al. work [l] , 
the affinity constant value for the binding of heme to 
the single binding center of hemopexin molecule was 
estimated as 1.9 X 1 014M-‘. It would be of interest to 
obtain heme-hemopexin on a preparative scale. 
Although affinity is high, all hemopexin failed to 
convert into heme-hemopexin in our study. Perhaps 
it would be necessary to find adequate incubation 
conditions for such a binding, and to dispose of a non- 
denaturing technique for preparing human hemopexin 
as did Bernard et al. for rat hemopexin [9]. 
This serum /3-glycoprotein binds circulating heme 
and transports it to the liver parenchymal cells [lo] . 
The interaction of heme with hemopexin produces 
changes in the tertiary structure of the protein [ 1 l] 
which possibly lead to recognition of the heme- 
hemopexin complex by hepatocytes. 
Data reported here may give arguments for two 
different interactions of hemopexin with heme. The 
site of interaction of polymers is not necessarily the 
same as in hemopexin-heme. This could explain why 
heme seems to be relatively accessible in Morgan et al. 
work on rabbit hemopexin. 
For polymer formation, heme remains on the out- 
side of the molecule, equally accessible to each protein 
molecule of the complex. This may correspond to the 
sterically unhindered heme-binding site found by 
Morgan et al. [ 121. For these authors, a relatively 
open heme-binding site perhaps helps either the recog- 
nition of the heme-hemopexin complex by hepato- 
cytes or the degradation of heme once the heme- 
hemopexin complex has entered the cell. 
Polymerization mechanism remains to be explained. 
It is different from a single aggregation after denatura- 
tion, since it is encountered in native serum. It would 
be a competition mechanism of several hemopexin 
molecules for one molecule of its ligand. This first site 
could be responsible for myoglobin and cytochrome c 
binding as shown by Biserte et al. [ 131. 
The second site on the inside of the molecule may 
correspond to a strong binding, responsible for transfer 
of heme from ferri-myoglobin and ferri-hemoglobin 
isolated chains to hemopexin [ I] . 
The intimate mechanism of such a strong binding 
is not clearly understood yet. It may be important, 
however, for heme-hemopexin complex not to be 
contaminated either by apo-hemopexin or by 
polymers for interpreting physico-chemical data. The 
relative importance of the three states of hemopexin 
may provide a tool for metabolic studies and is easy 
to determine with Laurel1 technique as reported here. 
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